Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.

Details

Serval ID
serval:BIB_7F8DDEE8DA1E
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Journal
Nature reviews. Clinical oncology
Author(s)
Martins F., Sofiya L., Sykiotis G.P., Lamine F., Maillard M., Fraga M., Shabafrouz K., Ribi C., Cairoli A., Guex-Crosier Y., Kuntzer T., Michielin O., Peters S., Coukos G., Spertini F., Thompson J.A., Obeid M.
ISSN
1759-4782 (Electronic)
ISSN-L
1759-4774
Publication state
Published
Issued date
09/2019
Peer-reviewed
Oui
Volume
16
Number
9
Pages
563-580
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Abstract
Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer therapy over the past decade. The indications for these agents continue to expand across malignancies and disease settings, thus reshaping many of the previous standard-of-care approaches and bringing new hope to patients. One of the costs of these advances is the emergence of a new spectrum of immune-related adverse events (irAEs), which are often distinctly different from the classical chemotherapy-related toxicities. Owing to the growing use of ICIs in oncology, clinicians will increasingly be confronted with common but also rare irAEs; hence, awareness needs to be raised regarding the clinical presentation, diagnosis and management of these toxicities. In this Review, we provide an overview of the various types of irAEs that have emerged to date. We discuss the epidemiology of these events and their kinetics, risk factors, subtypes and pathophysiology, as well as new insights regarding screening and surveillance strategies. We also highlight the most important aspects of the management of irAEs.
Keywords
Antineoplastic Agents, Immunological/adverse effects, Drug-Related Side Effects and Adverse Reactions/diagnosis, Drug-Related Side Effects and Adverse Reactions/epidemiology, Drug-Related Side Effects and Adverse Reactions/therapy, Humans, Immunologic Factors/adverse effects, Immunotherapy/adverse effects, Immunotherapy/methods, Neoplasms/drug therapy
Pubmed
Web of science
Create date
21/05/2019 7:28
Last modification date
12/02/2020 6:19
Usage data